Noninvasive monitoring of pulmonary fibrosis by targeting matrix metalloproteinases (MMPs)

Molecular Pharmaceutics

Volumn 10, Issue 6, 2013, Pages 2237-2247

  Cai, Yan ^a   Zhu, Lei ^b,c   Zhang, Fan ^c   Niu, Gang ^c   Lee, Seulki ^c   Kimura, Shioko ^a   Chen, Xiaoyuan ^c  

^a NATIONAL CANCER INSTITUTE   (United States)

^b XIAMEN UNIVERSITY   (China)

^c NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING   (United States)

Author keywords

activatable probe; matrix metalloproteinase; optical imaging; pulmonary fibrosis; secretoglobin 3A2

Indexed keywords

GELATINASE A; MACROGOL; METALLOPROTEINASE; SECRETOGLOBIN; SECRETOGLOBIN 3A2; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; ENZYME ACTIVITY; EX VIVO STUDY; FLUORESCENCE IMAGING; IN VIVO STUDY; LUNG FIBROSIS; MONITORING; MOUSE; NON INVASIVE PROCEDURE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ASSAY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TREATMENT RESPONSE; WESTERN BLOTTING;

ANIMALS; BLOTTING, WESTERN; IMMUNOHISTOCHEMISTRY; LUNG; MATRIX METALLOPROTEINASES; MICE; MICE, INBRED C57BL; PULMONARY FIBROSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SECRETOGLOBINS;

EID: 84878623838     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/mp300613x     Document Type: Article

References (44)

1. Martinez, F. J.; Donohue, J. F.; Rennard, S. I. The future of chronic obstructive pulmonary disease treatment-difficulties of and barriers to drug development Lancet 2011, 378 (9795) 1027-1037
2. American Thoracic Society. Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS). Am. J. Respir. Crit. Care Med. 2000, 161, (2 Pt 1), 646-664.
3. Thomeer, M.; Grutters, J. C.; Wuyts, W. A.; Willems, S.; Demedts, M. G. Clinical use of biomarkers of survival in pulmonary fibrosis Respir. Res. 2010, 11, 89
4. Lee, H. J.; Im, J. G.; Ahn, J. M.; Yeon, K. M. Lung cancer in patients with idiopathic pulmonary fibrosis: CT findings J. Comput. Assisted Tomography 1996, 20 (6) 979-982
5. Artinian, V.; Kvale, P. A. Cancer and interstitial lung disease Curr. Opin. Pulm. Med. 2004, 10 (5) 425-434
6. Selman, M.; King, T. E.; Pardo, A. Idiopathic pulmonary fibrosis: prevailing and evolving hypotheses about its pathogenesis and implications for therapy Ann. Intern. Med. 2001, 134 (2) 136-151
7. Dancer, R. C.; Wood, A. M.; Thickett, D. R. Metalloproteinases in idiopathic pulmonary fibrosis Eur. Respir. J. 2011, 38 (6) 1461-1467
8. Suga, M.; Iyonaga, K.; Okamoto, T.; Gushima, Y.; Miyakawa, H.; Akaike, T.; Ando, M. Characteristic elevation of matrix metalloproteinase activity in idiopathic interstitial pneumonias Am. J. Respir. Crit. Care Med. 2000, 162 (5) 1949-1956
9. Kessenbrock, K.; Plaks, V.; Werb, Z. Matrix metalloproteinases: regulators of the tumor microenvironment Cell 2010, 141 (1) 52-67
10. Zhu, L.; Wang, H.; Wang, L.; Wang, Y.; Jiang, K.; Li, C.; Ma, Q.; Gao, S.; Li, W.; Cai, M.; Niu, G.; Lee, S.; Yang, W.; Fang, X.; Chen, X. High-affinity peptide against MT1-MMP for in vivo tumor imaging J. Controlled Release 2011, 150 (3) 248-255
11. Stetler-Stevenson, W. G. Dynamics of matrix turnover during pathologic remodeling of the extracellular matrix Am. J. Pathol. 1996, 148 (5) 1345-1350
12. Kurata, K.; Maruyama, S.; Kato, S.; Sato, W.; Yamamoto, J.; Ozaki, T.; Nitta, A.; Nabeshima, T.; Morita, Y.; Mizuno, M.; Ito, Y.; Yuzawa, Y.; Matsuo, S. Tissue-type plasminogen activator deficiency attenuates peritoneal fibrosis in mice Am. J. Physiol.: Renal Physiol. 2009, 297 (6) F1510-F1517
13. Hirahara, I.; Ogawa, Y.; Kusano, E.; Asano, Y. Activation of matrix metalloproteinase-2 causes peritoneal injury during peritoneal dialysis in rats Nephrol., Dial., Transplant. 2004, 19 (7) 1732-1741
14. Masunaga, Y.; Hirahara, I.; Shimano, Y.; Kurosu, M.; Iimura, O.; Miyata, Y.; Amemiya, M.; Homma, S.; Kusano, E.; Asano, Y. A case of encapsulating peritoneal sclerosis at the clinical early stage with high concentration of matrix metalloproteinase-2 in peritoneal effluent Clin. Exp. Nephrol. 2005, 9 (1) 85-89
15. Oggionni, T.; Morbini, P.; Inghilleri, S.; Palladini, G.; Tozzi, R.; Vitulo, P.; Fenoglio, C.; Perlini, S.; Pozzi, E. Time course of matrix metalloproteases and tissue inhibitors in bleomycin-induced pulmonary fibrosis Eur. J. Histochem. 2006, 50 (4) 317-325
16. Corbel, M.; Belleguic, C.; Boichot, E.; Lagente, V. Involvement of gelatinases (MMP-2 and MMP-9) in the development of airway inflammation and pulmonary fibrosis Cell Biol. Toxicol. 2002, 18 (1) 51-61
17. Corbel, M.; Caulet-Maugendre, S.; Germain, N.; Molet, S.; Lagente, V.; Boichot, E. Inhibition of bleomycin-induced pulmonary fibrosis in mice by the matrix metalloproteinase inhibitor batimastat J. Pathol. 2001, 193 (4) 538-545
18. Tan, R. J.; Fattman, C. L.; Niehouse, L. M.; Tobolewski, J. M.; Hanford, L. E.; Li, Q.; Monzon, F. A.; Parks, W. C.; Oury, T. D. Matrix metalloproteinases promote inflammation and fibrosis in asbestos-induced lung injury in mice Am. J. Respir. Cell Mol. Biol. 2006, 35 (3) 289-297
19. Aso, Y.; Yoneda, K.; Kikkawa, Y. Morphologic and biochemical study of pulmonary changes induced by bleomycin in mice Lab. Invest. 1976, 35 (6) 558-568
20. Hattori, N.; Degen, J. L.; Sisson, T. H.; Liu, H.; Moore, B. B.; Pandrangi, R. G.; Simon, R. H.; Drew, A. F. Bleomycin-induced pulmonary fibrosis in fibrinogen-null mice J. Clin. Invest. 2000, 106 (11) 1341-1350
21. Zhu, L.; Huang, X.; Choi, K. Y.; Ma, Y.; Zhang, F.; Liu, G.; Lee, S.; Chen, X. Real-time monitoring of caspase cascade activation in living cells J. Controlled Release 2012, 163 (1) 55-62
22. Zhang, X. X.; Eden, H. S.; Chen, X. Peptides in cancer nanomedicine: drug carriers, targeting ligands and protease substrates J. Controlled Release 2012, 159 (1) 2-13
23. Cha, E. J.; Jang, E. S.; Sun, I. C.; Lee, I. J.; Ko, J. H.; Kim, Y. I.; Kwon, I. C.; Kim, K.; Ahn, C. H. Development of MRI/NIRF 'activatable' multimodal imaging probe based on iron oxide nanoparticles J. Controlled Release 2011, 155 (2) 152-158
24. Habibollahi, P.; Figueiredo, J. L.; Heidari, P.; Dulak, A. M.; Imamura, Y.; Bass, A. J.; Ogino, S.; Chan, A. T.; Mahmood, U. Optical imaging with a cathepsin B activated probe for the enhanced detection of esophageal adenocarcinoma by dual channel fluorescent upper GI endoscopy Theranostics 2012, 2 (2) 227-234
25. Choi, K. Y.; Swierczewska, M.; Lee, S.; Chen, X. Protease-activated drug development Theranostics 2012, 2 (2) 156-178
26. Jang, B.; Choi, Y. Photosensitizer-conjugated gold nanorods for enzyme-activatable fluorescence imaging and photodynamic therapy Theranostics 2012, 2 (2) 190-197
27. Melancon, M. P.; Zhou, M.; Li, C. Cancer theranostics with near-infrared light-activatable multimodal nanoparticles Acc. Chem. Res. 2011, 44 (10) 947-56
28. Zhu, L.; Xie, J.; Swierczewska, M.; Zhang, F.; Quan, Q.; Ma, Y.; Fang, X.; Kim, K.; Lee, S.; Chen, X. Real-time video imaging of protease expression in vivo Theranostics 2011, 1, 18-27
29. Kurotani, R.; Okumura, S.; Matsubara, T.; Yokoyama, U.; Buckley, J. R.; Tomita, T.; Kezuka, K.; Nagano, T.; Esposito, D.; Taylor, T. E.; Gillette, W. K.; Ishikawa, Y.; Abe, H.; Ward, J. M.; Kimura, S. Secretoglobin 3A2 suppresses bleomycin-induced pulmonary fibrosis by transforming growth factor beta signaling down-regulation J. Biol. Chem. 2011, 286 (22) 19682-19692
30. Moeller, A.; Ask, K.; Warburton, D.; Gauldie, J.; Kolb, M. The bleomycin animal model: a useful tool to investigate treatment options for idiopathic pulmonary fibrosis? Int. J. Biochem. Cell Biol. 2008, 40 (3) 362-382
31. Izbicki, G.; Segel, M. J.; Christensen, T. G.; Conner, M. W.; Breuer, R. Time course of bleomycin-induced lung fibrosis Int. J. Exp. Pathol. 2002, 83 (3) 111-119
32. Kurotani, R.; Tomita, T.; Yang, Q.; Carlson, B. A.; Chen, C.; Kimura, S. Role of secretoglobin 3A2 in lung development Am. J. Respir. Crit. Care Med. 2008, 178 (4) 389-398
33. Chiba, Y.; Kurotani, R.; Kusakabe, T.; Miura, T.; Link, B. W.; Misawa, M.; Kimura, S. Uteroglobin-related protein 1 expression suppresses allergic airway inflammation in mice Am. J. Respir. Crit. Care Med. 2006, 173 (9) 958-964
34. Lynch, D. A.; Newell, J. D.; Logan, P. M.; King, T. E., Jr.; Muller, N. L. Can CT distinguish hypersensitivity pneumonitis from idiopathic pulmonary fibrosis? AJR, Am. J. Roentgenol. 1995, 165 (4) 807-811
35. Win, T.; Lambrou, T.; Hutton, B. F.; Kayani, I.; Screaton, N. J.; Porter, J. C.; Maher, T. M.; Endozo, R.; Shortman, R. I.; Lukey, P.; Groves, A. M. (18)F-Fluorodeoxyglucose positron emission tomography pulmonary imaging in idiopathic pulmonary fibrosis is reproducible: implications for future clinical trials Eur. J. Nucl. Med. Mol. Imaging 2012, 39 (3) 521-528
36. 18F-fluorodeoxyglucose positron emission tomography for diagnosis and monitoring of pulmonary arterial hypertension Am. J. Respir. Crit. Care Med. 2012, 185 (6) 670-679
37. 18F-FDG PET in the diagnosis of pulmonary nodules with an initial standard uptake value less than 2.5 AJR, Am. J. Roentgenol. 2008, 191 (2) 475-479
38. Zhu, L.; Zhang, F.; Ma, Y.; Liu, G.; Kim, K.; Fang, X.; Lee, S.; Chen, X. In vivo optical imaging of membrane-type matrix metalloproteinase (MT-MMP) activity Mol. Pharmaceutics 2011, 8 (6) 2331-2338
39. Cortez-Retamozo, V.; Swirski, F. K.; Waterman, P.; Yuan, H.; Figueiredo, J. L.; Newton, A. P.; Upadhyay, R.; Vinegoni, C.; Kohler, R.; Blois, J.; Smith, A.; Nahrendorf, M.; Josephson, L.; Weissleder, R.; Pittet, M. J. Real-time assessment of inflammation and treatment response in a mouse model of allergic airway inflammation J. Clin. Invest. 2008, 118 (12) 4058-4066
40. Zucker, S.; Cao, J.; Chen, W. T. Critical appraisal of the use of matrix metalloproteinase inhibitors in cancer treatment Oncogene 2000, 19 (56) 6642-6650
41. Pavlaki, M.; Zucker, S. Matrix metalloproteinase inhibitors (MMPIs): the beginning of phase I or the termination of phase III clinical trials Cancer Metastasis Rev. 2003, 22 (2-3) 177-203
42. Vincenti, M. P.; Brinckerhoff, C. E. Transcriptional regulation of collagenase (MMP-1, MMP-13) genes in arthritis: integration of complex signaling pathways for the recruitment of gene-specific transcription factors Arthritis Res. 2002, 4 (3) 157-164
43. Baeten, J.; Haller, J.; Shih, H.; Ntziachristos, V. In vivo investigation of breast cancer progression by use of an internal control Neoplasia 2009, 11 (3) 220-227
44. Radisky, D. C.; Przybylo, J. A. Matrix metalloproteinase-induced fibrosis and malignancy in breast and lung Proc. Am. Thorac. Soc. 2008, 5 (3) 316-322